This Harvard-wide Program on Antibiotic Resistance (HPAR) proposal outlines the design and function of a novel, multidisciplinary, collaborative partnership to develop new approaches for treating and preventing multidrug resistant MRSA and VRE infection. Although discovery and delivery of novel and promising new compounds to the development pipeline is a major overall goal, because this is an academic effort, we also will add to the scientific knowledge that underpins the novel inhibitors developed; add to the understanding of resistance; and develop novel new tools for studying host-pathogen interactions and multidrug resistant pathogens. This project is being proposed by an accomplished group of scientists with extensive experience in the biochemistry of cell wall biosynthesis and use of that information to design screens and new inhibitors; the molecular biology of model host systems and the use of those systems in novel ways for screening compounds that hit complex targets with minimal toxicity; the development and application of high throughput next generation technologies; and the pathogenesis, biology and clinical treatment of infection caused by multidrug resistant staphylococci and enterococci. This scientific expertise is complemented by substantial administrative experience. The goal of the HPAR Administrative Core therefore is to oversee the smooth implementation of the research plan and deployment of resources, and to foster the cohesive and well functioning whole to achieve goals that are greater than the sum of the individual projects. This will be accomplished by achieving the following Specific Aims: 1) Provide program management, oversight, and compliance assurance, 2) Facilitate interactions between participants from the various components of the Harvard Medical School (including faculty located on the Longwood Campus, at Massachusetts General Hospital, and the Massachusetts Eye and Ear Infirmary), and the Mylonakis lab now in part at Brown University ? in a smooth and effective manner; 3) Provide critical infrastructure for fiscal management of the program; 4) Provide connectivity to and leverage other Harvard-wide initiatives, including the Microbial Sciences Initiative (MSI), and Catalyst Clinical and Translational Sciences Center; and 5) Provide a single point of contact and active coordination for on-going communication with NIAID, the Program Officer, and other NIAID staff and initiatives. The Administrative Core has managed the previous period in a way that led to a highly functioning, well integrated, and synergistic whole, and achieved additional aims generating resources and fostering data sharing with the greater scientific community. The proposed continuation period will build on these successes.

Public Health Relevance

The Harvard-wide Program on Antibiotic Resistance is designed to develop new approaches for treatment and prevention of multidrug resistant MRSA and VRE infection. The goal of the HPAR Administrative Core is to oversee the smooth implementation of the research plan and deployment of resources, and to foster the cohesive and well functioning whole to achieve goals that are greater than the sum of the individual projects. The Administrative Core has managed the previous period in a way that led to a highly functioning, well integrated, and synergistic whole, and achieved additional aims generating resources and fostering data sharing with the greater scientific community.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI083214-13
Application #
9996463
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2009-09-01
Project End
2021-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
13
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Massachusetts Eye and Ear Infirmary
Department
Type
DUNS #
073825945
City
Boston
State
MA
Country
United States
Zip Code
02114
Yuen, Grace J; Ausubel, Frederick M (2018) Both live and dead Enterococci activate Caenorhabditis elegans host defense via immune and stress pathways. Virulence 9:683-699
Wurster, Jenna I; Bispo, Paulo J M; Van Tyne, Daria et al. (2018) Staphylococcus aureus from ocular and otolaryngology infections are frequently resistant to clinically important antibiotics and are associated with lineages of community and hospital origins. PLoS One 13:e0208518
Keohane, Colleen E; Steele, Andrew D; Fetzer, Christian et al. (2018) Promysalin Elicits Species-Selective Inhibition of Pseudomonas aeruginosa by Targeting Succinate Dehydrogenase. J Am Chem Soc 140:1774-1782
Majed, Hiwa; Johnston, Tatiana; Kelso, Celine et al. (2018) Structure-activity relationships of pyrazole-4-carbodithioates as antibacterials against methicillin-resistant Staphylococcus aureus. Bioorg Med Chem Lett 28:3526-3528
Slatko, Barton E; Gardner, Andrew F; Ausubel, Frederick M (2018) Overview of Next-Generation Sequencing Technologies. Curr Protoc Mol Biol 122:e59
Tiwari, Kiran B; Gatto, Craig; Walker, Suzanne et al. (2018) Exposure of Staphylococcus aureus to Targocil Blocks Translocation of the Major Autolysin Atl across the Membrane, Resulting in a Significant Decrease in Autolysis. Antimicrob Agents Chemother 62:
Zhang, Sicai; Lebreton, Francois; Mansfield, Michael J et al. (2018) Identification of a Botulinum Neurotoxin-like Toxin in a Commensal Strain of Enterococcus faecium. Cell Host Microbe 23:169-176.e6
Santiago, Marina; Lee, Wonsik; Fayad, Antoine Abou et al. (2018) Genome-wide mutant profiling predicts the mechanism of a Lipid II binding antibiotic. Nat Chem Biol 14:601-608
Dabul, Andrei Nicoli Gebieluca; Avaca-Crusca, Juliana Sposto; Van Tyne, Daria et al. (2018) Resistance in In Vitro Selected Tigecycline-Resistant Methicillin-Resistant Staphylococcus aureus Sequence Type 5 Is Driven by Mutations in mepR and mepA Genes. Microb Drug Resist 24:519-526
Zheng, Zhaojun; Liu, Qingzhong; Kim, Wooseong et al. (2018) Antimicrobial activity of 1,3,4-oxadiazole derivatives against planktonic cells and biofilm of Staphylococcus aureus. Future Med Chem 10:283-296

Showing the most recent 10 out of 145 publications